Compare iShares MSCI South Korea ETF (EWY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI South Korea ETF trades at $177.25 (market cap $26.25B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: iShares MSCI South Korea ETF is the larger of the two by market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWY | NBIX | |
|---|---|---|
Market Cap | $26.25B | $14.36B |
Volume | 19,056,075 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $185.50 |
52-Week Low | $80.72 | $123.10 |
Typical Hold Time | 47 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) is trading at $177.18, down 3.56% amid broad Asian market weakness driven by rising oil prices and global bond yields. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights South Korea's KOSPI volatility, with semiconductor stocks facing pressure despite strong AI demand fundamentals and corporate earnings resilience.
The outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to memory cycle trends. While AI infrastructure spending provides long-term growth potential, near-term risks include rising borrowing costs, oil price volatility, and geopolitical tensions. The ETF's heavy technology weighting creates both opportunity and vulnerability to sector-specific headwinds.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
